| Phase 12 trials |
|
Phase 1
|
NCT06571422 |
Oct 2024 → Dec 2026 expected |
cancer |
Shanghai Junshi Bioscience Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06022250 |
Sep 2023 → Apr 2026 overdue |
cancer |
Shanghai Junshi Bioscience Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT07466160 |
Feb 2026 → Dec 2027 expected |
cancer |
Mabwell (Shanghai) Bioscience Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06953323 |
Jul 2025 → Jun 2029 expected |
neoplasm |
Wigen Biomedicine Technology (Shanghai) Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 212 trials |
|
Phase 2
|
NCT07690787 |
Jun 2026 → Dec 2027 expected |
nasopharyngeal carcinoma |
Chinese University of Hong Kong |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07503756 |
Apr 2026 → Dec 2027 expected |
colorectal cancer |
Shanghai Junshi Bioscience Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07480733 |
Apr 2026 → Nov 2027 expected |
cancer |
Shanghai Junshi Bioscience Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07309276 |
Jan 2026 → Nov 2027 expected |
lung cancer |
Shanghai Junshi Bioscience Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07045311 |
Sep 2025 → Mar 2028 expected |
triple-negative breast carcinoma |
Shanghai Junshi Bioscience Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06924606 |
Jul 2025 → Jul 2026 |
non-small cell lung carcinoma |
Shanghai Junshi Bioscience Co., Ltd. |
Terminated
|
No outcome recorded
Stop: Business |
|
Phase 2
|
NCT06969027 |
Jun → Nov 2025 overdue |
non-small cell lung carcinoma |
Shanghai Junshi Bioscience Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06954467 |
May 2025 → Dec 2027 expected |
hepatocellular carcinoma |
Shanghai Junshi Bioscience Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06885385 |
Apr 2025 → Nov 2026 expected |
colorectal cancer |
Shanghai Junshi Bioscience Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06944470 |
Apr 2025 → Sep 2026 overdue |
non-small cell lung carcinoma |
Shanghai Junshi Bioscience Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06868836 |
Mar 2025 → Sep 2026 overdue |
non-small cell lung carcinoma |
Shanghai Junshi Bioscience Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05582499 |
Nov 2022 → Dec 2027 expected |
HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma |
Fudan University |
Recruiting
|
No outcome recorded
|
|
| Phase 31 trial |
|
Phase 3
|
NCT07823348 |
Oct 2026 → Oct 2029 expected |
hepatocellular carcinoma |
Shanghai Junshi Bioscience Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|